TY - JOUR
T1 - Incidence of urinary retention during treatment with single tablet combinations of solifenacin plus tamsulosin OCASTM for up to 1 year in adult men with both storage and voiding LUTS
T2 - A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies
AU - Drake, Marcus J.
AU - Oelke, Matthias
AU - Snijder, Robert
AU - Klaver, Monique
AU - Traudtner, Klaudia
AU - van Charldorp, Karin
AU - Bongaerts, Dominique
AU - Van Kerrebroeck, Philip
PY - 2017/2/6
Y1 - 2017/2/6
N2 - Introduction The emergence of urinary retention (UR), specifically acute urinary retention (AUR), has been a concern when treating men with lower urinary tract symptoms (LUTS) with antimuscarinic drugs.Materials and methodsIn NEPTUNE (12-week, double-blind), men (>= 45 years) with LUTS were randomized to receive tamsulosin oral-controlled absorption system (TOCAS) 0.4 mg, fixed-dose combination (FDC) of solifenacin (Soli) 6 mg + TOCAS 0.4 mg, FDC Soli 9 mg + TOCAS 0.4 mg, or placebo. In NEPTUNE II (40-week, open-label extension of NEPTUNE), continuing patients received 4 -week FDC Soli 6 mg + TOCAS, then FDC Soli 6 mg or 9 mg + TOCAS for the remainder of the study, switchable every 3 months.ResultsAcross both studies, 1208 men received >= 1 dose of FDC Soli 6 mg or 9 mg + TOCAS for up to 52 weeks; 1199 men completed NEPTUNE and 1066 received >= 1 dose in NEPTUNE II. In total, 13 men (1.1%; 95% CI, 0.6%-1.8%) reported a UR event while receiving FDC, eight of which were AUR (0.7%; 95% CI, 0.3%-1.3%, incidence 7/1000 man-years). Six men reported UR events while taking Soli 6 mg + TOCAS (three AUR), and seven men reported a UR event while taking Soli 9 mg + TOCAS (five AUR). One man developed AUR while taking TOCAS alone and four reported UR (three AUR) during placebo run-in. Most AUR/UR events occurred within 4 months of treatment initiation.ConclusionsFDC Soli and TOCAS was associated with a low rate of UR and AUR in men with LUTS.
AB - Introduction The emergence of urinary retention (UR), specifically acute urinary retention (AUR), has been a concern when treating men with lower urinary tract symptoms (LUTS) with antimuscarinic drugs.Materials and methodsIn NEPTUNE (12-week, double-blind), men (>= 45 years) with LUTS were randomized to receive tamsulosin oral-controlled absorption system (TOCAS) 0.4 mg, fixed-dose combination (FDC) of solifenacin (Soli) 6 mg + TOCAS 0.4 mg, FDC Soli 9 mg + TOCAS 0.4 mg, or placebo. In NEPTUNE II (40-week, open-label extension of NEPTUNE), continuing patients received 4 -week FDC Soli 6 mg + TOCAS, then FDC Soli 6 mg or 9 mg + TOCAS for the remainder of the study, switchable every 3 months.ResultsAcross both studies, 1208 men received >= 1 dose of FDC Soli 6 mg or 9 mg + TOCAS for up to 52 weeks; 1199 men completed NEPTUNE and 1066 received >= 1 dose in NEPTUNE II. In total, 13 men (1.1%; 95% CI, 0.6%-1.8%) reported a UR event while receiving FDC, eight of which were AUR (0.7%; 95% CI, 0.3%-1.3%, incidence 7/1000 man-years). Six men reported UR events while taking Soli 6 mg + TOCAS (three AUR), and seven men reported a UR event while taking Soli 9 mg + TOCAS (five AUR). One man developed AUR while taking TOCAS alone and four reported UR (three AUR) during placebo run-in. Most AUR/UR events occurred within 4 months of treatment initiation.ConclusionsFDC Soli and TOCAS was associated with a low rate of UR and AUR in men with LUTS.
KW - BLADDER OUTLET OBSTRUCTION
KW - TRACT SYMPTOMS
KW - OVERACTIVE BLADDER
KW - GUIDELINES
KW - EFFICACY
KW - THERAPY
KW - SAFETY
KW - TRIAL
U2 - 10.1371/journal.pone.0170726
DO - 10.1371/journal.pone.0170726
M3 - Article
C2 - 28166296
SN - 1932-6203
VL - 12
JO - PLOS ONE
JF - PLOS ONE
IS - 2
M1 - 0170726
ER -